Technical Analysis for CASI - CASI Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | -0.19% | |
| Lower Bollinger Band Touch | Weakness | -0.19% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.69% | |
| Gapped Down | Weakness | -1.69% | |
| Gapped Up | Strength | -6.58% | |
| Fell Below 20 DMA | Bearish | -1.50% | |
| Shooting Star Candlestick | Bearish | -1.50% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.50% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.50% | |
| Earnings Movers | Other | -1.50% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Up 1% | about 4 hours ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
| Reversed from Down | 2 days ago |
Get a Trading Assistant
- Earnings date: 11/14/2024
CASI Pharmaceuticals, Inc. Description
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Disease Solid Tumors Autoimmune Disease Cancer Treatment Treatment Of Cancer Ovarian Cancer Leukemia Multiple Myeloma Platinum Stage Pharmaceutical Advanced Solid Tumors Cell Cycle Cyclacel Pyrrolidines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.4757 |
| 52 Week Low | 2.05 |
| Average Volume | 30,402 |
| 200-Day Moving Average | 4.97 |
| 50-Day Moving Average | 5.88 |
| 20-Day Moving Average | 5.78 |
| 10-Day Moving Average | 5.53 |
| Average True Range | 0.52 |
| RSI (14) | 41.52 |
| ADX | 20.24 |
| +DI | 14.07 |
| -DI | 15.98 |
| Chandelier Exit (Long, 3 ATRs) | 4.94 |
| Chandelier Exit (Short, 3 ATRs) | 6.33 |
| Upper Bollinger Bands | 6.41 |
| Lower Bollinger Band | 5.15 |
| Percent B (%b) | 0.09 |
| BandWidth | 21.80 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.0441 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.39 | ||||
| Resistance 3 (R3) | 6.35 | 5.93 | 6.20 | ||
| Resistance 2 (R2) | 5.93 | 5.65 | 5.95 | 6.13 | |
| Resistance 1 (R1) | 5.60 | 5.47 | 5.39 | 5.64 | 6.07 |
| Pivot Point | 5.18 | 5.18 | 5.08 | 5.20 | 5.18 |
| Support 1 (S1) | 4.85 | 4.90 | 4.64 | 4.89 | 4.45 |
| Support 2 (S2) | 4.43 | 4.72 | 4.45 | 4.39 | |
| Support 3 (S3) | 4.10 | 4.43 | 4.32 | ||
| Support 4 (S4) | 4.14 |
